Madrigal Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, MDGL, Madrigal Pharmaceuticals Inc, priceseries

Madrigal Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
90.66
Close
93.43
High
94.82
Low
90.66
Previous Close
91.23
Daily Price Gain
2.20
YTD High
100.86
YTD High Date
Mar 1, 2022
YTD Low
52.33
YTD Low Date
Jan 28, 2022
YTD Price Change
3.31
YTD Gain
3.67%
52 Week High
142.62
52 Week High Date
Apr 30, 2021
52 Week Low
52.33
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-21.89
52 Week Gain
-18.98%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 21. 2017
16.07
Oct 17. 2017
46.10
40 Trading Days
186.86%
Link
LONG
Dec 15. 2017
82.47
Jan 8. 2018
92.00
14 Trading Days
11.55%
Link
LONG
Jan 17. 2018
104.63
Feb 6. 2018
133.14
14 Trading Days
27.25%
Link
LONG
Jan 31. 2020
83.02
Feb 24. 2020
89.08
15 Trading Days
7.30%
Link
LONG
Apr 8. 2020
66.20
Apr 30. 2020
85.05
15 Trading Days
28.48%
Link
LONG
May 8. 2020
90.85
May 27. 2020
113.46
12 Trading Days
24.89%
Link
LONG
Sep 16. 2020
108.51
Sep 30. 2020
115.43
10 Trading Days
6.38%
Link
LONG
Nov 1. 2021
81.95
Nov 16. 2021
89.86
11 Trading Days
9.66%
Link
LONG
Dec 17. 2021
77.56
Jan 5. 2022
83.24
12 Trading Days
7.32%
Link
LONG
Feb 3. 2022
66.11
Mar 4. 2022
92.06
20 Trading Days
39.25%
Link
Company Information
Stock Symbol
MDGL
Exchange
NasdaqCM
Company URL
http://www.madrigalpharma.com
Company Phone
404-380-9263
CEO
Paul A. Friedman
Headquarters
Pennsylvania
Business Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA 19428
Sector
-
Industry Category
-
Industry Group
-
CIK
0001157601
About

Madrigal Pharmaceuticals, Inc. develops novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). It offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist with high liver uptake for the treatment of NASH and dyslipidemia or hypercholesterolemia including in heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH). The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Description

Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading